Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 127 participants.
Also called NCT03847506
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 127 participants
- Sponsor
- Registry
-
NCT03847506
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT03847506. Randomized; quadruple masking; primary purpose treatment. Start 2018-07-05 (actual); primary completion 2020-12-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Evaluate Efficacy and Safety of Ezetimibe/Rosuvastatin and Candesartan Cilexetil/Amlodipine Besylate Combination Tablets
- Acronym
- REVERT-K
- Condition
- Hypertension, Hyperlipidemia
- Intervention (Drug)
- Ezetimibe/Rosuvastatin
- Intervention (Drug)
- Candesartan cilexetil/Amlodipine besylate
- Intervention (Drug)
- Candesartan cilexetil
- Lead sponsor
- HK inno.N Corporation
Record details
- Record id
cardio:ct-nct03847506- Content hash
6b569776df8fbf8d67340f6d2f78a00cce74a08afab93d8df1ae9a10c8cf0569